endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

R&D channel feed

No­vo Nordisk takes For­ma’s sick­le cell treat­ment in­to Phase 3

6 months ago

Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe­si­ty

6 months ago
Pharma

J&J's Darza­lex hits pri­ma­ry end­point in Phase 3 ear­ly-stage mul­ti­ple myelo­ma tri­al

6 months ago

Gilead and Ar­cel­lx spot­light safe­ty of mul­ti­ple myelo­ma cell ther­a­py, dose first pa­tient in Phase 3

6 months ago
Cell/Gene Tx

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

6 months ago

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

6 months ago
Cell/Gene Tx

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

6 months ago

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

6 months ago
Manufacturing

BioN­Tech says VEGF bis­pe­cif­ic’s PD-L1 tar­get, com­bo plans will be its edge

6 months ago
Pharma

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

6 months ago
Pharma

Is there room for MASH drugs in a GLP-1 world?

6 months ago
Pharma
In Focus

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

6 months ago
Pharma

Cin­Rx touts pos­i­tive ear­ly-stage da­ta from two obe­si­ty can­di­dates

6 months ago

No­vo Nordisk claims late-stage MASH vic­to­ry, con­tin­u­ing GLP-1's ex­pan­sion

6 months ago

Es­sa’s shares tank as it looks for op­tions af­ter aban­don­ing prostate can­cer drug

6 months ago

UCB's an­ti-tau Alzheimer's pro­gram fails Phase 2 pri­ma­ry end­point, but high­lights pos­i­tive sec­on­daries

7 months ago

‘Im­i­ta­tion is best form of flat­tery’: Re­gen­eron CEO com­ments on Am­gen’s Eylea biosim­i­lar

7 months ago
Pharma

Take­da says mul­ti­year re­struc­tur­ing is 'on track'

7 months ago
Pharma

Am­gen makes pipeline cuts, but obe­si­ty plans re­main the fo­cus

7 months ago

Cor­cept miss­es pri­ma­ry end­point in sup­port­ive Cush­ing's syn­drome study

7 months ago

Com­pass Path­ways de­lays key Phase 3 psilo­cy­bin read­outs, spurring 30% lay­offs

7 months ago

Lex­eo shares ear­ly da­ta on Alzheimer’s gene ther­a­py 

7 months ago

Roche presents ear­ly-stage re­sults for lat­est amy­loid-based Alzheimer's at­tempt

7 months ago

At­las of tu­mors re­veals in 3D how cells change in­to can­cer

7 months ago
Discovery
Diagnostics
First page Previous page 19202122232425 Next page Last page
A service from the Financial Times